S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
pixel
Log in
ASX:PAA

PharmAust Limited (PAA.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.11
MA: A$0.11
A$0.11
52-Week Range N/A
Volume3.27 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

MarketRank

Overall MarketRank

0.58 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 8 6161 7412
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.12 million
Book ValueA$0.03 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Receive PAA News and Ratings via Email

Sign-up to receive the latest news and ratings for PAA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PharmAust Limited (PAA.AX) (ASX:PAA) Frequently Asked Questions

What stocks does MarketBeat like better than PharmAust Limited (PAA.AX)?

Wall Street analysts have given PharmAust Limited (PAA.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PharmAust Limited (PAA.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of PharmAust Limited (PAA.AX)'s key competitors?

Who are PharmAust Limited (PAA.AX)'s key executives?

PharmAust Limited (PAA.AX)'s management team includes the following people:
  • Dr. Roger Aston B.Sc., BSc (Hons), Ph.D., Exec. Chairman & Acting CEO (Age 65, Pay $284.7k)
  • Mr. Sam Michael Wright A.C.I.S., M.A.I.C.D., AFin, DipAcc, ACIS, MAICD, Fin. Director, Company Sec. & Director (Age 43, Pay $132.2k)
  • Dr. Richard Mollard, Chief Scientific Officer
  • Mr. Robert Charles Bishop, Exec. Director
  • Mr. Colin La Galia, Chief Exec. Officer of Epichem Pty Ltd
  • Ms. Rebecca McCrackan, Director of Epichem Pty Ltd

What is PharmAust Limited (PAA.AX)'s stock symbol?

PharmAust Limited (PAA.AX) trades on the ASX under the ticker symbol "PAA."

How big of a company is PharmAust Limited (PAA.AX)?

PharmAust Limited (PAA.AX) has a market capitalization of $0.00 and generates $4.12 million in revenue each year.

What is PharmAust Limited (PAA.AX)'s official website?

The official website for PharmAust Limited (PAA.AX) is www.pharmaust.com.

How can I contact PharmAust Limited (PAA.AX)?

The company can be reached via phone at 61 8 6161 7412.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.